US FDA declines to approve Regeneron's blood cancer therapy for second time
1. FDA declined Regeneron's blood cancer therapy approval, citing manufacturing site issues.
FAQ
Why Very Bearish?
Regeneron's repeated FDA rejections can significantly damage investor confidence, resembling past failures like Biomarin's failure to secure therapy approval, which led to dramatic stock declines.
How important is it?
Regeneron's mainstream product pipeline is heavily influenced by FDA approval outcomes, affecting stock valuation.
Why Short Term?
The immediate market reaction to FDA rejections typically results in quick negative price movements, as evidenced by similar cases in the biotech sector.